Prolongation of Pregnancy in Patients with HELLP Syndrome Using Methylprednisolone: A Retrospective Multicentric Analysis

{"Background": "HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is a severe manifestation of preeclampsia that endangers both mother and fetus. Immediate delivery has been the standard approach to prevent life-threatening maternal complications, but this results in iatrogenic preterm birth, which carries significant neonatal morbidity and mortality. The degree of prematurity, rather than maternal symptom severity, primarily determines neonatal outcomes. Corticosteroids have been proposed as a treatment to stabilize maternal condition and allow pregnancy prolongation, but evidence remains controversial. The 2019 German guidelines on Hypertension in Pregnancy state there is no evidence-based use of corticosteroids for HELLP syndrome treatment, based on NICE guidelines that note only improved platelet counts without clear clinical outcome benefits. This retrospective study examined whether methylprednisolone (MP) administration improves materno-fetal outcomes in HELLP syndrome.", "Methods": "The authors retrospectively analyzed 138 pregnant women with HELLP syndrome treated at university hospitals in Halle and Magdeburg, Germany between 1990 and 2013. The treatment group (n=65, Halle, 1999\u20132011) received intravenous MP 64 mg for 10 days with 50% dose reduction every other day. Control group 1 (n=45, Halle, 1990\u20132000 plus five untreated patients from 2001/2005/2008) underwent near immediate delivery without corticosteroids. Control group 2 (n=28, Magdeburg, 2007\u20132013) also underwent immediate delivery without corticosteroids. Pregnancy prolongation was attempted in the treatment group if patients had not reached 32 weeks gestation with stable maternal and fetal parameters. Exclusion criteria for prolongation included neurological symptoms, non-treatable hypertension, kidney insufficiency, pulmonary edema, DIC signs, progressive platelet decline, imminent fetal asphyxia, severe IUGR, anhydramnios, and intrauterine fetal death. Statistical analyses used chi-square test, Mann-Whitney U test, t-test with Bonferroni correction, Kaplan-Meier survival curves, and binary logistic regression (\u03b1=0.05).", "Key Results": "Pregnancy was prolonged by a median of 4 days (range 1\u201355 days) in the treatment group, with 35 of 65 patients (54%) achieving at least one day of prolongation. Platelet counts increased from 76,060 \u00b1 22,900/\u03bcL to 117,430 \u00b1 39,065/\u03bcL in the MP group within three days (p=0.0001), compared with an increase from 66,500 \u00b1 25,852/\u03bcL to 83,430 \u00b1 34,608/\u03bcL in control group 1 (p=0.013) and from 78,890 \u00b1 19,100/\u03bcL to 131,080 \u00b1 50,900/\u03bcL in control group 2 (p=0.0001). The mean difference in platelets between day 1 and day 3 was 38,500/\u03bcL vs 18,500/\u03bcL (p=0.023) vs 53,154/\u03bcL (p=0.194). AST levels decreased from 264 \u00b1 318 U/L to 72 \u00b1 60 U/L in the treatment group (p=0.0001) vs 240 \u00b1 198 U/L to 126 \u00b1 168 U/L in control group 1 (p=0.007). Severe neonatal complications were significantly reduced in the treatment group: sepsis 9.25% vs 24%; ventilation 44.6% vs 46.5%; infant death 1.6% vs 8.6%. Infants in the treatment group had a 65% lower relative risk of invasive ventilation (OR 0.355). No intrauterine fetal deaths occurred in the treatment group vs two (4.4%) in control group 1. Peripartum complications were absent in 52.3% of treatment group patients vs only 13% in control group 1 (p=0.0001). Anemia requiring transfusion occurred in 29.2% of the treatment group vs 64.4% of control group 1 (p<0.0001).", "Clinical Implications": "This study suggests that methylprednisolone treatment may allow safe prolongation of pregnancy in selected patients with HELLP syndrome who have stable maternal and fetal parameters, particularly those before 32 weeks gestation. The improved platelet counts, reduced transfusion requirements, and lower rates of neonatal complications (sepsis, ventilation, death) indicate potential benefits over immediate delivery. The authors argue that immediate delivery following HELLP diagnosis may no longer be justified in all cases, as the additional intrauterine time improves fetal outcomes. However, the study's retrospective design, potential selection bias, differences between control groups, and the lack of randomization limit the strength of these conclusions. The authors acknowledge that multicentric studies with larger patient numbers are needed to confirm results and optimize dosing. Current German and NICE guidelines do not recommend corticosteroids for HELLP syndrome treatment, citing only improved platelet counts without clear clinical outcome benefits. These findings challenge that position but require prospective validation before practice changes can be recommended."}